Octant, a next-generation, data-driven therapeutics company developing programmable biology and chemistry to build precision medicines for complex diseases, today announced an $80 million Series B financing round led by Catalio Capital Management, established a Deep Mutational Scanning biopharma partnership with Bristol Myers Squibb, and appointed biotech industry veteran Dean Artis as its first Chief Scientific Officer and renowned scientist Feng Zhang to its Scientific Advisory Board.

In addition to Catalio, the Series B financing included participation from Bristol Myers Squibb, and existing investors Andreessen Horowitz Bio Fund, Allen & Co., and 50 Years VC.

Octant Bio is a next-generation therapeutics company integrating novel and scaled experimental technologies (multiplexed measurements and high-throughput synthetic chemistry) with computation to solve complex challenges in drug discovery. Octant engineers drugs with novel mechanisms of actions guided by extensive proprietary datasets in engineered human cells that unlock insights between genomes, drug candidates, biochemical function, and disease phenotypes. The Octant platform uses synthetic biology, high throughput multiplexed assays, synthetic chemistry, and computation to engineer and interrogate drugs, proteins, and cellular pathways at unprecedented scales.